Clinical review report: Guselkumab (Tremfya) (Janssen Inc.)

The objective of this review was to perform a systematic review of the beneficial and harmful effects of guselkumab 100 mg administered as a subcutaneous (SC) injection for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy

Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, March 2018
Edition:Version: final
Series:CADTH common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:The objective of this review was to perform a systematic review of the beneficial and harmful effects of guselkumab 100 mg administered as a subcutaneous (SC) injection for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
Physical Description:1 PDF file (129 pages) illustrations